Long-term persistence of anti-HBs after hepatitis B vaccination among isolated anti-HBc positive adults in China: 8-years results
- 11 September 2020
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 17 (4) , 1190-1195
Abstract
The long-term persistence of hepatitis B surface antibody (anti-HBs) after hepatitis B vaccination among adults harboring isolated hepatitis B core antibody (anti-HBc) is not yet clarified. The present study aimed to assess the immunogenicity and persistence of antibodies in adults 8 years after vaccination. A total of 309 participants including 94 participants in the isolated anti-HBs group and 215 in the control group were recruited in this study. All subjects received three doses of hepatitis B vaccine (20 μg) at 0, 1, and 12 months, followed by testing for serological responses 1 month after the third vaccination. Subsequently, 154 participants were excluded because their anti-HBs data of 8 y after the first vaccination were missing. The prevalence of isolated anti-HBc was about 11.5%, the positive seroprotection rate was 72%, and the geometric mean titer (GMT) value of anti-HBs titer was 24.55 mIU/mL in the isolated anti-HBc group 8 y after three doses of vaccination. No significant difference was detected in the positive seroprotection rate (P = .434) and the GMT values of anti-HBs titers (P = .674) between the isolated anti-HBc and control groups after 8 y. In conclusion, isolated anti-HBc-positive subjects could achieve satisfactory long-term immune effects after hepatitis B vaccination. The GMT values of anti-HBs titers were lower than those of the control group at 1 month, but no significant difference was detected after 8 years.Keywords
Funding Information
- National Major Science and Technology Projects of China (2018ZX10715014)
- National Major Science and Technology Projects of China (2011ZX10004-901)
- National Major Science and Technology Projects of China (2017ZX10105001)
- National Major Science and Technology Projects of China (No. 2014ZX10004008)
- National Major Science and Technology Projects of China (No. 2013ZX10004-904)
This publication has 23 references indexed in Scilit:
- Responses to hepatitis B vaccine in isolated anti-HBc positive adultsHuman Vaccines & Immunotherapeutics, 2016
- Vaccination Against Hepatitis B Virus (HBV) in HIV-1–Infected Patients With Isolated Anti–HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective StudyThe Journal of Infectious Diseases, 2016
- Reprint of: Epidemiological serosurvey of Hepatitis B in China—Declining HBV prevalence due to Hepatitis B vaccinationVaccine, 2013
- Anti-hepatitis B core antibody is not required for prevaccination screening in healthcare workersVaccine, 2011
- The prevalence of “anti‐HBc alone” and HBV DNA detection among anti‐HBc alone in KoreaJournal of Medical Virology, 2010
- Antibody Levels and Protection after Hepatitis B Vaccine: Results of a 22‐Year Follow‐Up Study and Response to a Booster DoseThe Journal of Infectious Diseases, 2009
- Performance of an algorithm for the reentry of volunteer blood donors deferred due to false‐positive test results for antibody to hepatitis B core antigenTransfusion, 2008
- Response to Hepatitis B Vaccine in HBsAg/Anti-HBs Negative and Anti-HBc Positive SubjectsScandinavian Journal of Infectious Diseases, 2000
- Hepatitis B vaccination alone is not adequate for the categorizing of adult subjects with isolated anti‐HBcJournal of Gastroenterology and Hepatology, 1995
- Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: Implications in hepatitis B vaccination programsHepatology, 1988